'Who knows what they’re taking?': people risk the gray market for the newest weight-loss drug
Retatrutide, not yet approved by the FDA, is the latest wonder drug to shed pounds despite warnings from doctors
TL;DR
- People are buying retatrutide, a promising weight-loss drug, from unregulated gray market sellers, primarily in China, as it is not yet approved by the FDA.
- Physicians warn that using unapproved drugs without medical supervision poses serious health risks, including unknown contaminants and incorrect dosages.
- Retatrutide is a 'triple agonist' that targets three hormone receptors, potentially leading to greater weight loss than current prescription drugs like Ozempic.
- Eli Lilly is conducting clinical trials, and some patients are seeking access through limited early access programs, though these are difficult to qualify for.
- Lawsuits have been filed against companies selling retatrutide for 'research use only,' highlighting concerns about safety and efficacy from unregulated supply chains.
- Despite risks, some users report significant weight loss and improved body image, leading them to continue using the drug without medical documentation.
- Experts advocate for expedited FDA review of retatrutide to ensure safer access and prevent continued use of unregulated, potentially dangerous products.